Lung Cancer
Volume 69, Issue 2 , Pages 225-231 , August 2010

Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis

Received 16 August 2009 ,Revised 5 November 2009 ,Accepted 13 November 2009.

References 

  1. Knoepp UW, Ravenel JG. CT and PET imaging in non-small cell lung cancer. Crit Rev Oncol/Hematol. 2006;58:15–30
  2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl. 8):S4–S66
  3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: A Cancer J Clin. 2002;52:23–47
  4. Patz EF, Rossi S, Harpole DH, Herndon JE, Goodman PC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest. 2000;117:1568–1571
  5. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ (Clin Res Ed.). 2000;321:323–329
  6. Mroczko B, Szmitkowski M, Niklinski J. Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer. Clin Chem Lab Med. 1999;37:959–962
  7. Teare MD, Woll PJ. Genomic tests: unreliable for cancer? A focus on circulating DNA and lung cancer. Expert Rev Mol Diagn. 2007;7:699–702
  8. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006;52:1833–1842
  9. Stroun M, Anker P. Bacterial nucleic acid synthesis in plants following bacterial contact. Mol Gen Genet. 1971;113:92–98
  10. Schutz E, Urnovitz HB, Iakoubov L, Schulz-Schaeffer W, Wemheuer W, Brenig B. Bov-tA short interspersed nucleotide element sequences in circulating nucleic acids from sera of cattle with bovine spongiform encephalopathy (BSE) and sera of cattle exposed to BSE. Clin Diagn Lab Immunol. 2005;12:814–820
  11. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta. 2007;1775:181–232
  12. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem. 2002;48:1186–1193
  13. Xue X, Zhu YM, Woll PJ. Circulating DNA and lung cancer. Ann N Y Acad Sci. 2006;1075:154–164
  14. Fournie GJ, Courtin JP, Laval F, Chale JJ, Pourrat JP, Pujazon MC, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 1995;91:221–227
  15. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157–4164
  16. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ (Clin Res Ed.). 2003;326:41–44
  17. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25
  18. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9
  19. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–1316
  20. Lau J, Ioannidis JP, Balk EM, Milch C, Terrin N, Chew PW, et al. Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies. Ann Emergency Med. 2001;37:453–460
  21. Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667–676
  22. Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med. 1998;122:675–686
  23. Suzuki S, Moro-oka T, Choudhry NK. The conditional relative odds ratio provided less biased results for comparing diagnostic test accuracy in meta-analyses. J Clin Epidemiol. 2004;57:461–469
  24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed.). 1997;315:629–634
  25. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vullo S, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med. 2009;179:69–74
  26. Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci. 2008;1137:98–107
  27. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, et al Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer. 2004;111:746–749
  28. Tamkovich SN, Litviakov NV, Bryzgunova OE, Dobrodeev AY, Rykova EY, Tuzikov SA, et al. Cell-surface-bound circulating DNA as a prognostic factor in lung cancer. Ann N Y Acad Sci. 2008;1137:214–217
  29. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–4678
  30. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, et al Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2009;64:92–97
  31. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ. Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J. 2004;117:1485–1488
  32. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem. 2005;51:113–118
  33. Laktionov PP, Tamkovich SN, Rykova EY, Bryzgunova OE, Starikov AV, Kuznetsova NP, et al. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids. 2004;23:879–883
  34. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003;21:3902–3908
  35. Holdenrieder S, Stieber P, Bodenmuller H, Busch M, Fertig G, Furst H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001;95:114–120
  36. Yoon KA, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 2009;11:182–185
  37. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, et al Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol. 2008;3:365–373
  38. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650
  39. Ulivi P, Mercatali L, Zoli W, Dell’amore D, Poletti V, Casoni GL, et al. Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax. 2008;63:843–844
  40. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids—a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007;581:795–799
  41. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer (Amsterdam, Netherlands). 2005;49:1–12
  42. Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B, et al. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2009;66:245–249
  43. Vassilakopoulos T, Troupis T, Sotiropoulou C, Zacharatos P, Katsaounou P, Parthenis D, et al Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2001;32:137–144
  44. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T, Maehara Y. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surgery Today. 2004;34:896–901
  45. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48:1931–1937
  46. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–1135
  47. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ (Clin Res Ed.). 2001;323:157–162
  48. Gallagher EJ. Clinical utility of likelihood ratios. Ann Emergency Med. 1998;31:391–397
  49. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001;20:3625–3633

PII: S0169-5002(09)00586-8

doi: 10.1016/j.lungcan.2009.11.009

Lung Cancer
Volume 69, Issue 2 , Pages 225-231 , August 2010

Article Tools

* Image Usage & Resolution